nei THIS MONTH IN
PSYCHOPHARMACOLOGY
Browsing articles in "Psychotic Disorders"

 

FDA Committees Vote in Favor of a Combination of Olanzapine and Samidorphan
October 14, 2020   

Two advisory committees, the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, appointed by the US Food and Drug Administration have voted in favor of ALKS 3831, a combination of olanzapine and samidorphan. The...
 Continue reading
New Schizophrenia Treatment Guidelines Released by APA
September 14, 2020   

The American Psychiatric Association (APA) has just released its latest guidelines for the treatment of patients with schizophrenia. These new guidelines are the first APA schizophrenia guidelines to be published in over a decade. During that 10+ year interim, there have been many advancements in...
 Continue reading (Members only)
Olanzapine/Samidorphan Combo Found to Reduce Antipsychotic-Induced Weight Gain
September 1, 2020   

The combination of olanzapine, a dopamine D2 receptor antagonist, and samidorphan, an opioid receptor antagonist, is being developed for the treatment of schizophrenia and bipolar I disorder. Despite its efficacy, olanzapine is associated with significant weight gain and adverse metabolic effects that limit its clinical utility as a monotherapy. The combination of olanzapine and samidorphan has been shown to...
 Continue reading (Members only)
NEI Virtual Poster Library is Live!
July 13, 2020   

NEI has launched a Virtual Poster Library to fulfill the needs of poster presenters who had hoped to share their research and findings at medical conferences that have been cancelled due to the COVID-19 pandemic....
 Continue reading
Consensus Statement on Use of Antipsychotic Blood Levels
June 23, 2020   

It has been known that the quantification of antipsychotic levels in blood, known as therapeutic monitoring can be helpful in determining appropriate therapeutic dosing, and augmentation for treatment. It can be a useful tool for antipsychotics to manage challenging clinical scenarios, such as lack of therapeutic response, relapse, or adverse drug reactions (ADRs) related to antipsychotic treatment, especially...
 Continue reading (Members only)
Positive Results for a Non-D2 Antipsychotic
May 3, 2020   

The mainstay mechanism of action for available conventional and atypical antipsychotics typically involves antagonism or partial agonism of dopamine D2 receptors. However, currently available D2-binding antipsychotics often lack efficacy, especially in terms of negative and cognitive symptoms of schizophrenia, and may increase risk of potentially serious adverse events including motor symptoms and metabolic issues...
 Continue reading (Members only)
Transcranial Direct Current Stimulation (tDCS) as a Potential Treatment for Negative Symptoms of Schizophrenia
March 8, 2020   

In a recent double-blind randomized controlled study, the effects of transcranial direct current stimulation (tDCS) versus sham were examined as add-on treatment for negative symptoms...
 Continue reading (Members only)
FDA Warns of Serious Complications Following Clozapine-Induced Constipation
February 16, 2020   

The Food and Drug Administration strengthened an existing warning that constipation caused by the schizophrenia medicine clozapine can progress to...
 Continue reading (Members only)
Nationwide Cohort Study Shows Decreased Mortality With Long-term Antipsychotic Use
January 27, 2020   

Despite known adverse effects on cardiometabolic function, short-term antipsychotic use is also associated with lower mortality risk among persons with schizophrenia, and its effect of morbidity and mortality following long-term use is unclear. A nationwide observational study assessed the...
 Continue reading (Members only)
FDA Approves Lumateperone for Schizophrenia in Adults
January 14, 2020   

Schizophrenia is a lifelong illness affecting approximately 2.4 million Americans and is characterized by psychotic, negative, cognitive, and affective symptoms. Although there are numerous antipsychotic agents available to treat schizophrenia, optimized treatment for the individual patient varies and...
 Continue reading
12345678
Top of Page